Alcohol intake and long-term mortality risk after myocardial infarction in the Alpha Omega Cohort

Esther Cruijsen, Anne J de Ruiter, Leanne K Küpers, Maria C Busstra, and Johanna M Geleijnse

Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands

ABSTRACT

Background: Population-based studies generally show J-shaped associations between alcohol intake and mortality from cardiovascular disease (CVD). Little is known about alcohol and long-term mortality risk after myocardial infarction (MI).

Objectives: We examined alcohol intake in relation to all-cause, CVD, and ischemic heart disease (IHD) mortality in Dutch post-MI patients of the Alpha Omega Cohort.

Methods: The analysis comprised 4365 patients (60–80 years; 79% male) with an MI ≤ 10 years before study enrolment. We used a 203-item FFQ to assess alcohol (total ethanol) and dietary intakes over the past month. Patients were classified as nondrinkers (0 g/d; n = 956) or very light (<0 to 2 g/d; n = 385), light (M: >2 to 10 g/d; F: >2 to 5 g/d; n = 1125), moderate (M: >10 to 30 g/d; F: >5 to 15 g/d; n = 1207), or heavy drinkers (M: >30 g/d; F: >15 g/d; n = 692).

Results: Alcohol was consumed by 83% of males and 61% of females. During ~12 years of follow-up, 2035 deaths occurred, of which 903 were from CVD and 558 were from IHD. Compared to the (combined) reference group of nondrinkers (0 g/d; n = 956) or very light (<0 to 2 g/d; n = 385), light (M: >2 to 10 g/d; F: >2 to 5 g/d; n = 1125), moderate (M: >10 to 30 g/d; F: >5 to 15 g/d; n = 1207), or heavy drinkers (M: >30 g/d; F: >15 g/d; n = 692), HRs of mortality for alcohol intake were obtained from Cox models, adjusting for age, sex, education, smoking, BMI, physical activity, and dietary factors.

Conclusions: Light and moderate alcohol intakes were inversely associated with mortality risk in stable post-MI patients. These observational findings should be cautiously interpreted in light of the total evidence on alcohol and health. The Alpha Omega Cohort is registered at clinicaltrials.gov as NCT03192410.

Keywords: alcohol, myocardial infarction, ischemic heart disease, cardiovascular disease, mortality, prospective cohort study, Alpha Omega Cohort, patients

Introduction

Alcohol use is a major contributor to the global burden of disease, causing substantial health loss (1). For many cancers and other disorders, a gradual rise in mortality risk is observed with higher alcohol intake, starting from 0 intake (1). For cardiovascular disease (CVD), however, an as-yet-unexplained J-shaped association between alcohol intake and mortality has been found in observational studies, suggesting that light or moderate drinking is beneficial compared to not drinking and heavy drinking (1–3). Whether alcohol indeed offers cardiovascular protection at lower intake levels is highly debated because of potential confounding and other biases. Nondrinkers in cohort studies may not only include life-long abstainers, but also “sick quitters” who stopped drinking because of health problems and individuals who deliberately underreport their (heavy) alcohol use. The latter groups are generally at increased mortality risks, leading to biased risk estimates for 0 alcohol intake. Methods to deal with abstainer bias in observational studies are often not successful, also due to limitations of self-administered questionnaires (4). Randomized controlled trials of long-term alcohol use and clinical CVD endpoints are lacking because of ethical and feasibility constraints. Thus, despite extensive observational findings on alcohol intake and mortality risk after myocardial infarction, the role of alcohol use remains uncertain. A better understanding of the role of alcohol in cardiovascular disease is needed to improve management of patients after acute coronary syndromes.
research, the role of alcohol in the development of CVD is still
not fully understood.

Patients already suffering from CVD are at an increased
risk of recurrent events and premature mortality (5). Next
to medical treatment, improvement of diet and lifestyle is a
cornerstone of cardiovascular risk management (6). The
European Society of Cardiology encourages patients with chronic
coronary syndromes to limit their alcohol intake to less than
100 g/week (15 g/day) if alcohol is consumed (6). Cardiovascular
organizations in Europe and the United States do not explicitly
promote total abstinence for ischemic heart disease (IHD)
patients who currently drink (6, 7).

Costanzo et al. (8) performed a meta-analysis of prospective
cohort studies on alcohol use and mortality in CVD patients,
mainly suffering from IHD. In 8 cohorts involving more than
16,000 patients from the United States, the United Kingdom,
Sweden, and Japan (predominantly male), light and moderate
alcohol intakes were consistently inversely associated with CVD
and total mortality risks during a median follow-up of ~5 years.
In a subgroup analysis of post–myocardial infarction (post-MI)
patients, risks were 19% lower for CVD mortality and 22%
lower for total mortality for alcohol intakes around 12 g/d
(9–12). Inverse associations were observed for all levels of
intake up to 24 g/d for CVD mortality and 32 g/d for total
mortality. Risk estimates for alcohol and mortality in these
cohorts were adjusted for age, sex (if applicable), smoking, BMI,
physical activity, socioeconomic factors, and diabetes, but not for
diet.

Since alcohol use is often linked to dietary habits (13), residual
confounding in these studies cannot be excluded. Therefore, we
set up an observational study of alcohol use and mortality risk
in IHD patients, overcoming major shortcomings of previous
studies, including short-term follow-ups, incomplete assessments
of alcohol intake and dietary confounders, and a lack of
investigation of abstainer bias. In 4365 post-MI patients of the
Alpha Omega Cohort, we examined habitual alcohol intakes and
risks of mortality during 12 years of follow-up, with extensive
adjustments for diet, lifestyle, and other potential confounders.
Alcohol use was studied in relation to all-cause, CVD, and IHD
mortality, and sensitivity analyses were performed to gain insight
into a potential abstainer bias.

Methods

Study design and participants

The Alpha Omega Cohort is a prospective cohort study of
4837 Dutch males and females aged 60–80 years with a verified
history of MI for ≤10 years prior to study enrolment (2002–
2006). During the first 3 years of follow-up, patients participated
in a randomized controlled trial of omega-3 fatty acids, showing
no effect on major cardiovascular events (14, 15). Follow-up
research for cause-specific mortality started in 2002, and is still
ongoing. Patients provided written consent, and the study was
approved by a central ethics committee (Haga Hospital) and
by the ethics committee of participating hospitals. Excessive
habitual alcohol intake of ≥7 drinks per day was an exclusion
criterion for the study. For the present analysis, we further
excluded patients with missing data on alcohol intake (n = 453)
or with implausible energy intakes (<800 or >8000 kcal/d for
males and <600 or >6000 kcal/d for females; n = 19), leaving
4365 patients (Supplemental Figure 1).

Assessment of diet and alcohol intake

Dietary data were collected at baseline using a 203-item
FFQ, aggregated in 24 food groups (16). This FFQ was an
adapted and extended version of a reproducible and biomarker-
validated FFQ. The Pearson correlation coefficient between the
FFQ and the dietary history method was 0.83 for total energy
intake (17). The FFQ contained questions on the frequencies and
quantities of foods and beverages consumed during the previous
month. All returned questionnaires were checked by trained
dietitians who obtained additional information when data were
missing or unclear. Double entry of the FFQ data was performed.
Questionnaire data were linked to the Dutch Food Composition
Database (NEVO 2006) to calculate nutrient and total energy
intakes (18). Salt intake was only calculated from foods, since
the FFQ did not include questions on discretionary salt use.

The FFQ included separate questions for intakes of beer
(alcoholic, nonalcoholic), wine (red, rose, white, fortified), and
liquor (e.g., whisky, rum, gin, cognac) and alcoholic long drinks.
Patients could also indicate alcoholic drinks that were not
mentioned as examples. For all alcoholic beverages, patients
reported the number of glasses they consumed on a daily or
weekly basis during the previous month (not this month, ≤1 per
week, 2–3 per week, 4–6 per week, 1 per day, 2–3 per day, 4–5
per day, or ≥6 per day). Total alcohol intake (g/d) was calculated
as the sum of ethanol from all alcoholic beverages, considering
10 grams of alcohol in a standard drink in the Netherlands.
Additional information on alcohol use was obtained from a self-
administered lifestyle questionnaire, where patients indicated
whether they were a lifetime abstainer, former drinker, or current
drinker and whether they had sometimes consumed >6 glasses
of alcohol on 1 day in the past year, which we defined as binge
drinking. The correlation for alcohol intake (g/d) from the FFQ
and the lifestyle questionnaire was 0.81.

Alcohol intake was classified into sex-specific categories
because females may have higher and more prolonged blood
levels of alcohol than males for the same dose of alcohol per kg
of body weight (19). In men, drinking categories were defined as
0 g/d (none), >0 to 2 g/d (very light), >2 to 10 g/d (light), >10 to
30 g/d (moderate), and >30 g/d (heavy). In women, the categories
were 0 g/d (none), >0 to 2 g/d (very light), >2 to 5 g/d (light),
>5 to 15 g/d (moderate), and >15 g/d (heavy). Nondrinkers are a
heterogenous group that not only includes true abstainers but also
“sick quitters” and alcohol use deniers. The additional category
of very light drinking (>0 to 2 g/d) was used as an alternative
reference group in the data analysis to avoid “abstainer bias,” as
described below.

Mortality follow-up

This study focuses on all-cause mortality as the primary
endpoint and CVD and IHD mortality as secondary endpoints.
The vital status of patients was monitored through linkage with
municipal registries, from baseline through 31 December 2018.
Follow-up for cause-specific mortality occurred in 3 phases.
From 2002–2009 (Alpha Omega Trial), information was obtained from the national mortality registry [Statistics Netherlands (CBS)], treating physicians, and close family members. Primary and contributing causes of death were coded by an independent Endpoint Adjudication Committee, as described previously (14, 15). After the trial through 2012, data on the primary and contributing causes of death were obtained from CBS. From 2013 onwards, CBS provided data on the primary cause of death only, and treating physicians were asked to fill out an additional cause-of-death questionnaire (response rate: 67%), which was coded by study physicians who were not involved in the current analysis. The endpoint of CVD or IHD mortality was allocated to all patients for whom it was a primary or contributing cause of death, based on any of the data sources.

Mortality coding was performed according to the International Classification of Diseases, Tenth Revision (20), where CVD mortality comprised codes I20–I25 (ischemic heart disease), I46 (cardiac arrest), R96 (sudden death, undefined), I50 (heart failure), and I60–I69 (stroke) and IHD mortality comprised codes I20–I25, I46, and R96.

Other measurements

At baseline, data were collected on demographic and anthropometric factors, lifestyle, current health status, and medical history. BMI was calculated from the measured weight and height, and a BMI ≥ 30 kg/m² was classified as obese. Smoking status comprised 4 categories: current; former, quit ≤ 10 years ago; former, quit > 10 years ago; and never. In current smokers, the daily amount of cigarettes (including rolling tobacco) was assessed. Pack years of smoking were calculated for current smokers by multiplying the number of smoking years with the daily amount of cigarettes, divided by 20. Pack years could not be calculated for former smokers, due to a lack of data. Physical activity was determined using the validated Physical Activity Scale of the Elderly (21), and divided into 3 categories: low [no activity or only light activity; ≤ 3 Metabolic Equivalent Tasks (METs)], intermediate [moderate or vigorous activity (> 3 METs on > 0 to < 5 days per week), and high [moderate or vigorous activity (> 3 METs on ≥ 5 days per week). Educational level was divided into 3 categories: low (primary or lower secondary education), moderate (higher secondary or lower tertiary education), or high (higher tertiary education). Self-rated health was assessed with the question “how do you rate your overall health at this moment?,” using a 5-point scale ranging from poor to excellent. Self-reported medication use was checked by research nurses and coded according to the Anatomical Therapeutic Chemical (ATC) classification system (22).

Serum lipids and plasma glucose were analyzed from non-fasting blood using standard kits and an automated analyzer (Hitachi 912; Roche Diagnostics). Blood pressure was measured twice using an automatic device and averaged (HEM-711; Omron). Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or use of an antihypertensive medication (ATC codes C02, C03, C07, C08, and C09). Diabetes mellitus was defined as fasting (> 4 hours) plasma glucose ≥ 7.0 mmol/L, nonfasting plasma glucose ≥ 11.1 mmol/L, use of an anti-diabetic medication (ATC code A10), or a self-reported physician diagnosis of diabetes.

Statistical analysis

Patient characteristics at baseline are presented in alcohol categories as means ± SDs for normally distributed variables, medians (IQRs) for nonnormally distributed variables, and n (%) for categorical variables.

Cox proportional hazard models were used to estimate HRs with 95% CIs for all-cause, CVD, and IHD mortality in categories of alcohol intake, using the combined none and very light drinking categories (alcohol: 0 to 2 g/d) as the reference. Additional analyses were performed in which nondrinkers (0 g/d) and very light drinkers (> 0 to 2 g/d) were studied as separate categories, using very light drinkers as the reference, to obtain insight into potential abstainer bias. The proportional hazard assumption was checked by log-minus-log plots and was met. Person-years were calculated as the number of years between the date of inclusion and the date of death, or the end of follow-up (31 December 2018), whichever occurred first. Patients who died due to a competing risk were censored, in addition to those who were lost to follow-up and survived until the end of follow-up. One patient was lost to follow-up and censored after 2.9 years.

HRs were adjusted for age and sex (Model 1). Model 2 additionally included obesity (yes/no), smoking (4 categories), physical activity (3 categories), and educational level (3 categories). Data on the amount of cigarettes and pack years were only available for current smokers, and the addition of these variables to the model did not impact the HRs. Therefore, these variables were left out of the model. Model 3 additionally included dietary factors: total energy intake (kcal/d, excluding energy from ethanol) and intakes of sugar-sweetened beverages (g/d), coffee (g/d), red and processed meat (g/d), fish (g/d), whole grains (g/d), and fruits and vegetables (g/d). Binge drinking (yes/no) was added to Model 3 (along with habitual alcohol intake categories) to examine whether this behavior was independently associated with mortality endpoints. Missing data (all at random) for BMI (n = 6), smoking (n = 1), physical activity (n = 25), and educational level (n = 24) were imputed with the age- and sex-specific median (for BMI) or mode (categorical covariates) to maintain these patients in the multivariable analysis.

Restricted cubic splines (RCS) were used to investigate associations between continuous alcohol intake and mortality and establish a potential threshold or nonlinear associations for males and females separately. For the RCS analysis, the reference value of 0 g/d was set and knots were placed at the 5th, 50th, and 95th percentiles. The Wald chi-square test was carried out for testing nonlinearity of the associations (23).

Effect measure modifications by sex, obesity, and smoking status were assessed by means of a stratified analysis, using the fully adjusted model. Sensitivity analyses were performed after exclusion of (1 by 1) 474 former drinkers, 1028 patients with poor or moderate self-rated health, and 883 patients with diabetes. Further sensitivity analyses were performed after excluding the first 2 years of follow-up, during which 155 deaths occurred, and excluding 633 patients with an MI < 1 year prior to enrolment to investigate whether risk estimates could be biased by deteriorating health.

Two-sided P values < 0.05 were considered statistically significant. All statistical analyses were performed using the statistical software SAS (version 9.4; SAS Institute Inc.). Forest
Results

Table 1 presents baseline characteristics for 4365 patients, overall and in categories of alcohol intake. Patients were 69.0 ± 5.6 years old on average, and 79% were male. At study entry, the median time since an MI was 3.7 years. Of the included patients, 16% were current smokers and 50% quit smoking ≤10 years ago, 20% had diabetes, 24% were obese, and 23% had poor or moderate self-rated health.

Alcohol was consumed by 83% of males and 61% of females (Supplemental Table 1). Males and females predominantly consumed wine (55% and 48%, respectively) and beer (52% and 7%, respectively). Of 956 nondrinkers, 384 patients (40%) were former drinkers. Those with a higher alcohol intake were slightly younger and more often men. They were more likely to be highly educated, to be physically active, and to have very good or excellent self-reported health, and were less likely to have diabetes or obesity. Among drinkers, the median alcohol intakes were 11.5 g/d in males and 5.8 g/d in females.

During a median follow-up of 12.4 years (48,473 person-years), 2035 deaths occurred, including 903 from CVD and 558 from IHD. Table 2 presents HRs for all-cause, CVD, and IHD mortality in categories of total alcohol intake. Light and moderate alcohol intake compared to the reference (0 to 2 g/d; i.e., nondrinkers or very light drinkers combined) was associated with a lower risk of all-cause, CVD, and IHD mortality in the fully adjusted models. For all-cause mortality, the lowest HR was observed for those with moderate alcohol intake (HR, 0.85; 95% CI, 0.75–0.96) compared to those with none or very light alcohol intake (Supplemental Figure 2). After excluding nondrinkers from the reference group, the HRs remained largely unchanged but the associations were no longer significant (Supplemental Table 2). For CVD mortality, the lowest HRs were observed for those with light alcohol intake (HR, 0.80; 95% CI, 0.67–0.96), which was also the case for IHD mortality (HR, 0.79; 95% CI, 0.63–0.99), compared to nondrinkers or very light drinkers (Table 2; Supplemental Figure 2). Also for these outcomes, excluding nondrinkers from the reference group yielded similar HRs, but the associations were no longer significant (Supplemental Table 2). For heavy alcohol intake, the associations were also inverse but nonsignificant for all endpoints.

When analyzed continuously, using RCS, alcohol intake was nonlinearly, inversely associated with all-cause, CVD, and IHD mortality (all P values < 0.05) in males with the lowest risk, observed at ~ 20 g/d (Figure 1A–C). For the smaller group of females, no significant associations were observed for continuous alcohol intake and all endpoints (Figure 1D–F).

Subgroup analyses

In women, heavy drinking compared to the reference category (0 to 2 g/d; nondrinkers or very light drinkers), was associated with an increased mortality risk, especially from IHD (HR, 1.89; 95% CI, 1.10–3.26; Supplemental Figure 3). Lower drinking categories were not associated with mortality in women. In men, HRs were similar as compared to the total cohort, but with inverse associations for heavy drinking reaching statistical significance for all-cause mortality (HR, 0.83; 95% CI, 0.70–0.97) and CVD mortality (HR, 0.77; 95% CI, 0.60–0.99) compared to the reference.

In patients with obesity, a trend towards an increased risk of all-cause, CVD, and IHD mortality was observed with heavy drinking, although it was not significant (Supplemental Figure 4). Moderate drinking was associated with lower risks of CVD and IHD mortality. In patients without obesity, associations were roughly similar compared to the total cohort and, additionally, heavy drinking was inversely associated with all-cause mortality (HR, 0.81; 95% CI, 0.68–0.96) and CVD mortality (HR, 0.73; 95% CI, 0.57–0.95).

HRs for alcohol intake with long-term mortality endpoints were not modified by smoking status, although associations in both smokers and nonsmokers were no longer significant (Supplemental Figure 5).

Sensitivity analyses

Excluding former drinkers from the none or very light reference group (0 to 2 g/d) attenuated the inverse associations for light (HR, 0.93; 95% CI, 0.81–1.06) and moderate drinkers (HR, 0.90; 95% CI, 0.90–1.03) with all-cause mortality, but associations for CVD and IHD mortality remained comparable with HRs for the total cohort (Supplemental Figures 6 and 7). After excluding patients with poor or moderate self-rated health, light and moderate drinking were more inversely associated, with HRs for light drinking of 0.82 (95% CI, 0.71–0.95) for all-cause mortality, 0.72 (95% CI, 0.57–0.89) for CVD mortality, and 0.65 (95% CI, 0.49–0.86) for IHD mortality compared to the total cohort (Supplemental Figure 5). After excluding patients with diabetes, associations for light drinking but not moderate drinking were attenuated, with HRs of 0.95 (95% CI, 0.82–1.09) for all-cause mortality, 0.88 (95% CI, 0.72–1.09) for CVD mortality, and 0.86 (95% CI, 0.66–1.13) for IHD mortality compared to the total cohort (Supplemental Figure 5).

HRs for binge drinking in the fully adjusted model (including alcohol intake categories) were 1.02 (95% CI, 0.89–1.17) for all-cause mortality, 1.07 (95% CI, 0.87–1.31) for CVD mortality, and 1.09 (95% CI, 0.85–1.14) for IHD mortality. HRs did not essentially differ after excluding the first 2 years of follow-up and after excluding patients with an MI < 1 year before enrolment (Supplemental Figure 8).

Discussion

In the Alpha Omega Cohort of Dutch post-MI patients with ~12 years follow-up, light or moderate alcohol intake was inversely associated with long-term risks of all-cause, CVD, and IHD mortality. In men, we observed nonlinear, inverse associations with these mortality endpoints, with the lowest HRs for alcohol intakes around 20 g/d. In the smaller group of women, associations for light and moderate alcohol intakes were also inverse, but weak and nonsignificant, with the lowest HRs around 10 g/d. For high alcohol intake, the mortality risk (especially from IHD) was increased in women.

In a meta-analysis by Costanzo et al. (4) of prospective cohort studies specifically in CVD patients, light and moderate
TABLE 1  Baseline characteristics of 4365 patients of the Alpha Omega Cohort, overall and in categories of alcohol intake1

| Alcohol intake, g/d | Total (n = 4365) | None (n = 956) | Very light (n = 385) | Light (n = 1125) | Moderate (n = 1207) | Heavy (n = 692) |
|--------------------|-----------------|---------------|-------------------|-----------------|--------------------|---------------|
| None               |                 | 69.0 ± 5.6    | 70.0 ± 5.5        | 69.4 ± 5.6      | 68.7 ± 5.4         | 68.9 ± 5.6    |
| Females            |                 | 933 (21)      | 364 (38)          | 126 (33)        | 142 (13)           | 197 (16)      |
| Dutch ethnicity    |                 | 4315 (99)     | 933 (98)          | 376 (98)        | 1,112 (99)         | 1,202 (100)   |
| BMI, kg/m²         |                 | 27.7 ± 3.8    | 28.2 ± 4.5        | 28.3 ± 4.0      | 27.7 ± 3.5         | 27.3 ± 3.4    |
| Obese              |                 | 1032 (24)     | 281 (29)          | 114 (30)        | 261 (23)           | 231 (19)      |
| Age, years         |                 | 69.0 ± 5.6    | 70.0 ± 5.5        | 69.4 ± 5.6      | 68.7 ± 5.4         | 68.9 ± 5.6    |
| Females            |                 | 933 (21)      | 364 (38)          | 126 (33)        | 142 (13)           | 197 (16)      |
| Dutch ethnicity    |                 | 4315 (99)     | 933 (98)          | 376 (98)        | 1,112 (99)         | 1,202 (100)   |
| BMI, kg/m²         |                 | 27.7 ± 3.8    | 28.2 ± 4.5        | 28.3 ± 4.0      | 27.7 ± 3.5         | 27.3 ± 3.4    |
| Obese              |                 | 1032 (24)     | 281 (29)          | 114 (30)        | 261 (23)           | 231 (19)      |
| Educational level1 |                 |               |                   |                 |                    |               |
| Low                |                 | 2439 (56)     | 662 (70)          | 245 (64)        | 644 (58)           | 597 (50)      |
| Moderate           |                 | 1367 (31)     | 230 (24)          | 106 (28)        | 367 (33)           | 407 (34)      |
| High               |                 | 535 (12)      | 56 (6)            | 34 (9)          | 107 (10)           | 198 (16)      |
| Smoking status4    |                 |               |                   |                 |                    |               |
| Never              |                 | 722 (16)      | 227 (24)          | 80 (21)         | 182 (16)           | 174 (14)      |
| Former             |                 | 767 (18)      | 130 (14)          | 46 (12)         | 244 (22)           | 239 (20)      |
| Current            |                 | 713 (16)      | 172 (18)          | 68 (18)         | 165 (15)           | 189 (16)      |
| Cigarette use in current smokers, n/d | | | | | | |
| Low                |                 | 11 ± 7        | 11 ± 6            | 9 ± 6           | 10 ± 6             | 10 ± 6        |
| Intermediate       |                 | 1635 (38)     | 279 (29)          | 118 (31)        | 448 (40)           | 499 (41)      |
| High               |                 | 922 (21)      | 154 (16)          | 76 (20)         | 250 (22)           | 286 (24)      |
| Time since last myocardial infarction, years | | | | | | |
| Poor or moderate   |                 | 1010 (23)     | 322 (34)          | 110 (29)        | 225 (20)           | 234 (19)      |
| Good               |                 | 2827 (65)     | 569 (60)          | 247 (64)        | 745 (66)           | 795 (66)      |
| Very good or excellent | | | | | | |
| Plasma glucose, mmol/L | | | | | | |
| Systolic           |                 | 141.9 ± 21.5  | 141.4 ± 22.7      | 140.3 ± 20.4    | 141.5 ± 20.6       | 141.8 ± 21.2  |
| Diastolic          |                 | 80.2 ± 11.1   | 78.6 ± 11.7       | 78.9 ± 11.0     | 80.8 ± 10.8        | 80.4 ± 10.8   |
| Hypertension, n (%) |                 | 4161 (95)     | 920 (96)          | 368 (96)        | 1065 (95)          | 1147 (95)     |
| Serum lipids, mmol/L | | | | | | |
| LDL cholesterol12  |                 | 4.2 ± 0.8     | 3.4 ± 0.6         | 3.2 ± 0.4       | 3.1 ± 0.3          | 2.8 ± 0.2     |
| HDL cholesterol13  |                 | 1.3 ± 0.3     | 1.2 ± 0.3         | 1.2 ± 0.3       | 1.2 ± 0.3          | 1.2 ± 0.3     |
| Triglycerides13     |                 | 1.9 ± 1.0     | 2.0 ± 1.1         | 2.1 ± 1.2       | 1.9 ± 1.0          | 1.8 ± 0.92    |
| Self-rated health7  |                 |               |                   |                 |                    |               |
| Poor or moderate    |                 | 1010 (23)     | 322 (34)          | 110 (29)        | 225 (20)           | 234 (19)      |
| Good               |                 | 2827 (65)     | 569 (60)          | 247 (64)        | 745 (66)           | 795 (66)      |
| Very good or excellent | | | | | | |
| Hypertension, n (%) |                 | 4161 (95)     | 920 (96)          | 368 (96)        | 1065 (95)          | 1147 (95)     |
| Serum lipids, mmol/L | | | | | | |
| LDL cholesterol12  |                 | 4.2 ± 0.8     | 3.4 ± 0.6         | 3.2 ± 0.4       | 3.1 ± 0.3          | 2.8 ± 0.2     |
| HDL cholesterol13  |                 | 1.3 ± 0.3     | 1.2 ± 0.3         | 1.2 ± 0.3       | 1.2 ± 0.3          | 1.2 ± 0.3     |
| Use of cardiovascular medication, n (%) | | | | | | |
| Antihypertensive medication | | | | | | |
| Lipid-modifying medication | | | | | | |
| Characteristics                        | Total (n = 4365) | None (n = 956) | Very light (n = 385) | Light (n = 1125) | Moderate (n = 1207) | Heavy (n = 692) |
|---------------------------------------|-----------------|----------------|---------------------|-----------------|-------------------|-----------------|
|                                       |                 |                |                     |                 |                   |                 |
| Dietary factors                       |                 |                |                     |                 |                   |                 |
| Total energy, kcal/d                  | 1802 ± 500      | 1734 ± 500     | 1760 ± 521          | 1836 ± 501      | 1861.5 ± 500      | 1761 ± 469     |
| Alcohol intake in drinkers, g/d       | 10.4 (4.5–23.1) | —              | 1.3 (1.1–1.8)       | 4.9 (3.4–7.4)   | 13.9 (11.3–20.5)  | 36.9 (32.5–46.5)|
| Beer drinker, n                       | 1841 (42)       | 91 (24)        | 616 (55)            | 683 (57)        | 451 (65)          |                 |
| Beer in drinkers, g/d                 | 72 (28–142)     | 28 (28–28)     | 72 (28–72)          | 72 (28–200)     | 72 (28–500)       |                 |
| Wine drinker, n                       | 2324 (53)       | 160 (42)       | 694 (62)            | 910 (75)        | 560 (81)          |                 |
| Vine in drinkers, g/d                 | 49 (31–124)     | 17 (14–17)     | 31 (17–45)          | 88 (45–124)     | 309 (76–323)      |                 |
| Binge drinking, n                     | 811 (19)        | 18 (2)         | 15 (4)              | 284 (24)        | 304 (44)          |                 |
| Coffee drinker, n                     | 4164 (95)       | 885 (93)       | 362 (94)            | 1078 (96)       | 1165 (97)         | 674 (97)        |
| Tea, g/d                              | 375 (375–563)   | 375 (375–563)  | 375 (375–563)       | 375 (375–563)   | 375 (375–563)     | 375 (375–563)   |
| Milk, g/d                             | 150 (45–450)    | 150 (21–450)   | 150 (54–450)        | 150 (54–450)    | 150 (54–450)      | 150 (54–450)    |
| Sugar-sweetened beverages, g/d        | 128 (42–219)    | 115 (21–235)   | 128 (42–213)        | 138 (54–220)    | 146 (54–228)      | 108 (41–188)    |
| Whole grains, g/d                     | 113 (88–160)    | 99 (81–158)    | 106 (88–160)        | 122 (88–163)    | 118 (88–161)      | 101 (88–158)    |
| Fruit and vegetables, g/d             | 219 (144–379)   | 213 (130–386)  | 226 (143–397)       | 222 (153–378)   | 223 (159–387)     | 215 (132–320)   |
| Red and processed meat, g/d           | 68 (40–94)      | 61 (31–86)     | 65 (36–93)          | 67 (40–92)      | 70 (43–96)        | 72 (48–100)     |
| Fish, g/d                             | 14 (5–19)       | 11 (1–17)      | 11 (4–17)           | 12 (5–18)       | 15 (5–21)         | 16 (10–27)      |
| Sodium, g/d                           | 2.1 (1.7–2.6)   | 2.0 (1.6–2.5)  | 2.1 (1.6–2.5)       | 2.2 (1.7–2.6)   | 2.2 (1.8–2.7)     | 2.2 (1.8–2.7)   |

1 Values are means ± SDs for normally distributed variables, medians (IQRs) for skewed variables, or n (%) for categorical variables, unless otherwise indicated. MET, metabolic equivalent task.
2 Missing data for 6 patients.
3 Obesity was defined as a BMI ≥ 30 kg/m2.
4 Missing data for 24 patients.
5 Missing data for 1 patient.
6 Calculation of pack years; pack years could not be calculated for former smokers due to a lack of data.
7 Missing data for 25 patients.
8 Low activity was defined as ≤3 METs, intermediate activity as >3 METs on >0 to <5 days per week, and high activity as >3 METs on ≥5 days per week.
9 Missing data for 18 patients.
10 Metabolic equivalent task. Myocardial infarction was based on a verified clinical diagnosis < 10 years before study enrolment.
11 Defined as self-reported physician diagnosis, use of antidiabetic medication, or elevated plasma glucose (≥7.0 mmol/L if fasted >4 hours or ≥11.1 mmol/L if nonfasted).
12 Defined as sometimes drinking >6 glasses on 1 day.
13 Sodium intake was only estimated from foods, since discretionary salt use could not be assessed by means of the FFQ.
Alcohol and mortality after myocardial infarction

TABLE 2 HRs for alcohol intake and all-cause, CVD, and IHD mortality in 4365 patients from the Alpha Omega Cohort

| Total alcohol intake, g/d | None or very light, 0–2 (n = 1341) | Light, M: >2 to 10; F: >2 to 5 (n = 1125) | Moderate, M: >10 to 30; F: >5 to 15 (n = 1207) | Heavy, M: >30; F: >15 (n = 692) |
|--------------------------|----------------------------------|------------------------------------------|------------------------------------------|-------------------------------|
| Male sex (%)             | 851 (63)                         | 983 (87)                                 | 1010 (84)                                | 588 (85)                      |
| Person-years             | 14,271                           | 12,781                                   | 13,570                                   | 7852                          |
| Median intake, g/d       |                                  |                                          |                                          |                               |
| Males                    | 0                                | 5.7                                      | 15.4                                     | 38.3                          |
| Females                  | 0                                | 3.2                                      | 10.0                                     | 30.9                          |
| All-cause mortality      |                                  |                                          |                                          |                               |
| Cases                    | 712                              | 495                                      | 523                                      | 305                           |
| Model 11,2               | 1.00                             | 0.80 (0.72–0.91)                         | 0.78 (0.70–0.88)                         | 0.85 (0.74–0.98)              |
| Model 21,3               | 1.00                             | 0.87 (0.77–0.98)                         | 0.85 (0.75–0.95)                         | 0.91 (0.79–1.04)              |
| Model 31,4               | 1.00                             | 0.87 (0.78–0.98)                         | 0.85 (0.75–0.96)                         | 0.91 (0.79–1.04)              |
| CVD mortality            |                                  |                                          |                                          |                               |
| Cases                    | 332                              | 207                                      | 231                                      | 133                           |
| Model 11,2               | 1.00                             | 0.74 (0.62–0.88)                         | 0.76 (0.64–0.90)                         | 0.82 (0.67–1.01)              |
| Model 21,3               | 1.00                             | 0.81 (0.67–0.97)                         | 0.83 (0.70–0.99)                         | 0.86 (0.70–1.06)              |
| Model 31,4               | 1.00                             | 0.80 (0.67–0.96)                         | 0.82 (0.69–0.98)                         | 0.87 (0.70–1.08)              |
| IHD mortality            |                                  |                                          |                                          |                               |
| Cases                    | 204                              | 129                                      | 137                                      | 88                            |
| Model 11,2               | 1.00                             | 0.72 (0.57–0.90)                         | 0.71 (0.57–0.88)                         | 0.85 (0.66–1.09)              |
| Model 21,3               | 1.00                             | 0.78 (0.62–0.99)                         | 0.78 (0.62–0.98)                         | 0.89 (0.69–1.16)              |
| Model 31,4               | 1.00                             | 0.79 (0.63–0.99)                         | 0.79 (0.63–0.99)                         | 0.92 (0.70–1.20)              |

1HRs (95% CIs) were obtained from Cox proportional hazards models, using the lowest category as the reference. CVD, cardiovascular disease; IHD, ischemic heart disease.

2Adjusted for age and sex.

3Adjusted as in Model 1 plus obesity, smoking status, physical activity, and education level.

4Adjusted as in Model 2 plus energy intake, excluding energy from alcohol, and intakes of sugar-sweetened beverages, red and processed meat, whole grains, fruits, vegetables, coffee, tea, milk, fish, and salt from foods.

alcohol intakes were associated with lower risks of all-cause and CVD mortality during a median follow-up of ~5 years. In their subgroup analysis of post-MI patients from the United States and Europe, the maximum observed risk reductions were 19% for CVD mortality and 22% for total mortality for alcohol intakes around 12 g/d, corresponding to roughly 1 standard drink per day (24). These results were mainly driven by data in men, since women were not included or were underrepresented in the different cohorts. The present analysis in the Alpha Omega Cohort showed 15%–20% lower risks of CVD and all-cause mortality for light or moderate drinking. In our study of predominantly male patients (79%), the lowest mortality risks were observed for alcohol intakes around 20 g/d, corresponding to 2 drinks a day. Because of the relatively wide CIs around the HRs, our data would also be compatible with lower “optimal” doses of alcohol (e.g., 1 drink a day), in line with the meta-analysis by Costanzo et al. (4). In our subgroup analysis of women, the mortality risks were lowest for alcohol intakes around 10 g/d, but the HRs were not statistically significant due to small numbers.

The lower mortality risk in light and moderate drinkers, as observed in cohort studies, is highly debated (3, 4). Residual confounding may be present due to incomplete adjustments for socioeconomic status and lifestyle factors. In the present analysis of the Alpha Omega Cohort, we were able to adjust for many potential confounders, including dietary factors. Reporting bias may occur in cohort studies, with (heavy) drinkers being misclassified in the nondrinking reference category. We therefore repeated our analysis in drinkers only, using patients with the lowest alcohol intake (>0 to 2 g/d) as the reference group. This yielded similar inverse associations for all-cause, CVD, and IHD mortality, although the findings were no longer significant due to a smaller sample size.

Wood et al. (2) performed a population-based pooling study of almost 600,000 current alcohol users (i.e., nondrinkers and former drinkers excluded) from high-income countries. For incident CVD (fatal and nonfatal combined), a J-shaped association was observed, with the lowest risks (~10%) for alcohol intakes around 15 g/d. We obtained similar findings for light or moderate drinking in the Alpha Omega Cohort when excluding nondrinkers and former drinkers from the analysis, using very light drinkers (>0 to 2 g/d) as the reference group. For all-cause mortality, however, no protective associations were found in the pooling study among drinkers, while we still observed a 15% lower risk when comparing light and moderate drinking with very light drinking. This discrepancy may be due to our cohort of post-MI patients, in which all-cause mortality was largely driven by preexisting IHD. The impact of non-CVD mortality causes, such as cancer, may have been larger in the population-based pooling study.

Patients in the no-drinking category could have stopped drinking because of ill health (“sick quitters”), which may lead to biased risk estimates. Excluding former drinkers (n = 384; 40% of the no-drinking category), however, did not change the results, making this source of bias unlikely in our analysis. Furthermore, we did a sensitivity analysis excluding the first 2 years of...
FIGURE 1 Associations of alcohol intake with all-cause, CVD, and IHD mortality in 4365 patients from the Alpha Omega Cohort. Lines are restricted cubic splines, showing continuous associations, with 3 knots located at the 5th, 50th, and 95th percentiles. The y-axis shows the predicted HRs for mortality for any value of alcohol intake, compared to the reference value set at 0 g/d. HRs are adjusted for age; sex; obesity; smoking; physical activity; education level; energy intake, excluding energy from alcohol; and intakes of sugar-sweetened beverages, red and processed meat, whole grains, fruits, vegetables, coffee, tea, milk, fish, and salt from foods. CVD, cardiovascular disease; IHD, ischemic heart disease.

Follow-up. Patients who died during this period were more likely to have poor health at baseline. This did not change the results. Excluding patients who recently had an MI (<1 year prior to study enrolment) also yielded similar results. When stratifying our analysis for self-rated health, inverse associations with mortality for light or moderate alcohol intakes were observed in patients with both good/excellent health and poor/moderate health. These findings support the view...
that our risk estimates were not influenced by deteriorating health.

Causal effects may be disentangled from associations in a Mendelian randomization (MR) study with genetically determined or predicted alcohol intake, which is not prone to abstainer bias and confounding factors (25). In a 10-year MR study of >500,000 healthy Chinese males and females with low habitual alcohol intake, no relationship was found between alcohol intake (as a continuous variable) and incident MI (fatal and nonfatal; RR, 0.96; 95% CI, 0.78–1.18; per 40 g/d) (26). This finding is against the hypothesis of a cardioprotective effect of light and moderate drinking. Results from the MR study, however, are hard to compare to the present study because of different populations (healthy Chinese individuals compared with Dutch post-MI patients), levels of alcohol intake, and outcomes (incident MI compared with mortality). Furthermore, the field of MR research is still advancing, and various underlying assumptions for MR studies have been questioned (27). MR studies across a wide range of alcohol intakes, accounting also for nonlinear relationships, are needed to further clarify the effect of genetically influenced alcohol use on mortality risks.

On one hand, alcohol intake may induce favorable changes in the cardiovascular system, such as improvement of the blood lipid profile, elevation of adiponectin, lowering of plasma fibrinogen, and a lower endocrine response to stress, which would support a cardioprotective effect (28, 29). On the other hand, alcohol raises blood pressure, which is a major risk factor for CVD (30, 31), and increases the risk of atrial fibrillation (32). Alcohol is harmful for the liver and brain and contributes to the development of cancers (1). It also increases the risk of injuries, and misuse of alcohol causes social harm (33). Therefore, even if a protective effect of alcohol intake against CVD were present, minimizing the intake of alcohol may be recommended.

Our study has several limitations. Misclassification of patients in alcohol categories could have occurred, because alcohol intake was only assessed at baseline, and seasonal variations in individual intake were not captured by our FFQ. This misclassification, which is likely to be nonsystematic, may have attenuated the HRs for alcohol in relation to mortality endpoints. Also, we were unable to examine drinking patterns or alcohol use in the context of meals. Heavy drinking could not adequately be studied, because patients with excessive alcohol intake (7 or more glasses per day) were not eligible for enrolment in the Alpha Omega Cohort. This also hampered the study of binge drinking, for which we found neutral associations, while other studies pointed at binge drinking as an independent risk factor for mortality and IHD risks (34, 35). The Alpha Omega Cohort comprises predominantly male, older, post-MI patients from the Netherlands. CVD risk factors were largely controlled by state-of-the-art drug treatment. Medication use and the underlying atherothrombotic disease process could have affected the sensitivity to alcohol in our patients. Findings from the present study cannot be generalized to healthy populations and IHD patients from non-Caucasian origin, and women were also underrepresented in our study. Sample sizes in the subgroup analyses were relatively small, and results in smokers and patients with obesity and diabetes should therefore be interpreted with caution. Strengths of our study include the unique cohort of post-MI patients, with ~12 years of follow-up for mortality endpoints and only 1 patient lost to follow-up. Detailed data collection enabled elaborate adjustments for dietary and lifestyle factors in the analyses. Alcohol intake was adequately assessed using a comprehensive FFQ and an additional lifestyle questionnaire. Sensitivity analyses were defined a priori to investigate potential biases.

In conclusion, we observed lower risks of all-cause, CVD, and IHD mortality in post-MI patients with light or moderate alcohol intakes compared to nondrinkers. These observational findings should be interpreted with caution in light of the total evidence on alcohol use and health, also taking into account the potential social harms of alcohol intake.

The authors’ responsibilities were as follows—EC: conducted the research, interpreted the data, wrote the manuscript, and had primary responsibility for the final content; EA, AE, LK: performed the data analysis; AE, EA, LK: drafted the first version of the manuscript; MCB: supervised the data analysis; MCB, LK, JMG: critically reviewed the manuscript; JMG: conceived and designed the study, performed the data acquisition, and had primary responsibility for the final content; and all authors: read and approved the final manuscript. The authors report no conflicts of interest.

Data Availability

Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.

References

1. Griswold MG, Fullman N, Hawley C, Ariam N, Zimsen SR, Tymeson HD, Venkateswaran V, Tapp AD, Forouzanfar MH, Salama JS. Alcohol use and burden for 195 countries and territories. 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet North Am Ed 2018;392(10152):1015–35.

2. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S. Risk thresholds for alcohol consumption: Combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet North Am Ed 2018;391(10129):1513–23.

3. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ 2011;342:d671.

4. Costanzo S, De Gaetano G, Di Castelnuovo A, Djourssé L, Poli A, Velden DP. Moderate alcohol consumption and lower total mortality risk: Justified doubts or established facts? Nutr Metab Cardiovasc Dis 2019;29(10):1003–8.

5. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN. Heart disease and stroke statistics–2021 update: A report from the American Heart Association. Circulation 2021;143(8):e254–743.

6. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuijsset T. ESC guidelines for the diagnosis and management of chronic coronary syndromes: The task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020;41(3):407–77.

7. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hindereiter AL. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60(24):e44–e164.

8. Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, De Gaetano G. Cardiovascular and overall mortality risk in relation to alcohol
consumption in patients with cardiovascular disease. Circulation 2010;121(17):1951–9.

9. Muntwyler J, Hennekens CH, Buring JE, Gaziano JM. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet North Am Ed 1998;352(9144):1882–5.

10. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Prior alcohol consumption and mortality following acute myocardial infarction. JAMA 2001;285(15):1965–70.

11. Aguilar D, Skali H, Møyë LA, Lewis EF, Gaziano JM, Rutherford JD, Hartley LH, Randall OS, Geltman EM, Lamas GA. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol 2004;43(11):2015–21.

12. Janszky I, Ljung R, Ahmve S, Hallqvist J, Bennet AM, Mukamal KJ. Alcohol and long-term prognosis after a first acute myocardial infarction: The SHEEP study. Eur Heart J 2008;29(1):45–53.

13. Kesse E, Clavel-Chapelon F, Slimani N, van Liere M, Group EN. Do eating habits differ according to alcohol consumption? Results of a study of the French cohort of the European Prospective Investigation into Cancer and Nutrition (E3N-EPIC). Am J Clin Nutr 2001;74(3):322–7.

14. Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D, Group AOT. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: Design and baseline characteristics of the Alpha Omega Trial. Am Heart J 2010;159(4):539–546.e2.

15. Kromhout D, Giltay EJ, Geleijnse JM. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363(21):2015–26.

16. Sjötsma FP, Soedamah-Muthu SS, De Goede J, Oude Griep LM, Geleijnse JM, Giltay EJ, De Boer MJ, Jacobs DR, Jr, Kromhout D. Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the-art drug treatment. Am J Clin Nutr 2015;102(6):1527–33.

17. Feunekes GI, Van Staveren WA, De Vries J, Burema J, Hautvast J. Relative and biomarker-based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. Am J Clin Nutr 1993;58(4):489–96.

18. Dutch Nutrition Center. Dutch Food Composition Table Vol. 1. Voedingsstoffenbestand/NEVO Foundation; 2006.

19. Baroona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes Z, Schaefer C, Lieber CS. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001;25(4):502–7.

20. World Health Organization. International statistical classification of diseases and related health problems. Geneva, Switzerland: World Health Organization; 2004.

21. Schuit AJ, Schouten EG, Westerterp KR, Saris WH. Validity of the Physical Activity Scale for the Elderly (PASE): According to energy expenditure assessed by the doubly labeled water method. J Clin Epidemiol 1997;50(5):541–6.

22. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses-ATC/DDD. Oslo, Norway: World Health Organization; 2009.